Welcome to our dedicated page for Bio Rad Labs SEC filings (Ticker: BIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Bio-Rad is a Delaware corporation based in Hercules, California, and its filings offer detailed information on its life science research and clinical diagnostics businesses, financial performance, and material corporate events.
Investors can review current reports on Form 8-K, where Bio-Rad reports items such as quarterly financial results, supplemental earnings presentations, leadership changes, acquisitions, and other significant events. Recent 8-K filings reference the announcement of results for quarters ended June 30 and September 30, the completion of the acquisition of Stilla Technologies, and the appointment of senior executives.
In addition to current reports, users may consult annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the SEC feed) for more extensive discussion of segment performance in the Life Science and Clinical Diagnostics groups, risk factors, accounting policies, and details on items such as the company’s investment in Sartorius. These filings also describe Bio-Rad’s use of non-GAAP financial measures and provide reconciliations to GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify items such as revenue trends, margin drivers, and notable changes in investments or capital structure. The platform also surfaces insider transaction reports on Form 4 when they are filed, allowing users to track equity transactions by Bio-Rad officers and directors. Together, these tools make it easier to interpret BIO’s SEC filings without reading every line of the underlying documents.
Allison Schwartz, a director of Bio-Rad Laboratories (BIO), reported insider transactions on Form 4 covering September 1, 2025. The filing shows vesting-driven acquisitions: 147 shares of Class A common stock were added on vesting of restricted stock units at no cash cost and 31, 42, and 74 RSUs vested (representing rights to 31, 42 and 74 shares). Following the transactions, Ms. Schwartz beneficially owned 1,452 shares of Class A common stock directly. The report also discloses a sale of 55 shares at $297.88 each, reducing direct holdings to 1,397 shares. The filing reflects routine executive equity compensation and a small open-market sale.
Bio-Rad insider transaction summary: EVP and President, LSG Barry James reported transactions on 09/01/2025 involving Bio-Rad Laboratories Class A common stock (BIO). The filing shows 602 shares were acquired and added to his direct holdings following the vesting of restricted stock units, increasing his direct beneficial ownership to 748.555 shares. The filing also reports a disposition of 217 shares sold at $297.88 per share, leaving 531.555 shares after that sale. Separately, the report lists restricted stock unit activity: 178 units vested (converted to 0 shares remaining), 174 units vested and remain as 174 shares, and 250 units vested increasing total RSU-derived shares to 502. The transactions are documented on a Form 4 signed 09/02/2025.
Colleen Corey, Executive Vice President, Global Human Resources of Bio-Rad Laboratories, reported insider transactions dated 09/01/2025. The filing shows 1,102 shares of Bio-Rad Class A common stock were acquired on vesting of restricted stock units at no cash price, and 398 shares were disposed of at $297.88 per share. Following the transactions, the reporting person beneficially owned 19,581 shares after the vesting event and 19,183 shares after the sale, as shown in the form.
The filing also reports restricted stock unit activity: vesting-related entries of 254, 347, and 501 RSUs tied to prior grants from 2021, 2022, and 2023, with the explanatory note that each RSU represents a contingent right to one share.
Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories (BIO), reported changes in his beneficial ownership on September 1, 2025. He acquired 6,353 Class A shares on vesting of restricted stock units and had 3,084 Class A shares disposed of at $297.88 per share. After these transactions he directly owned 444,591 Class A shares. The filing also reports direct ownership of 361,466 Class B shares and indirect holdings of 13,006 Class B shares (by spouse) and 4,060,054 Class B shares (by Blue Raven Partners, L.P.). Several restricted stock unit vesting events are noted, reflecting prior grants from 2021–2023 that vest in annual installments.
Bio-Rad Laboratories, Inc. filed a report describing an informational investor webinar focused on its Droplet Digital™ PCR (ddPCR™) product portfolio held on August 26, 2025. The webinar included a presentation and Q&A session with President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju. A live webcast and a replay, along with the slide presentation, are or will be available for up to a year in the Investor Relations section of the company’s website under “Events & Presentations.” The slide deck for the webinar is also provided as Exhibit 99.1, with the disclosure treated as furnished under Regulation FD rather than filed for liability purposes.
Rajat Mehta, listed as Executive Vice President, GBL Commercial Operations at Bio-Rad Laboratories (BIO), filed an initial Form 3 reporting the Section 16 beneficial-ownership status. The event date is 08/04/2025 and the form is signed 08/14/2025. The filing states no securities beneficially owned (0 shares) by the reporting person, with ownership shown as direct (D) where applicable.